Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Choueiri Toni K.; Fishman Mayer N.; Escudier Bernard; McDermott David F.; Drake Charles G.; Kluger Harriet; Stadler Walter M.; Perez-Gracia Jose Luis; McNeel Douglas G.; Curti Brendan; Harrison Michael R.; Plimack Elizabeth R.; Appleman Leonard; Fong Lawrence; Albiges Laurence; Cohen Lewis; Young Tina C.; Chasalow Scott D.; Ross-Macdonald Petra; Srivastava Shivani; Jure-Kunkel Maria; Kurland John F.; Simon Jason S.; Sznol Mario

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

【24h】

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

机译：尼伐单抗在转移性肾细胞癌中的免疫调节活性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell carcinoma (mRCC). We investigated immunomodulatory activity of nivolumab in a hypothesis-generating prospective mRCC trial.

机译：目的：抗PD-1免疫检查点抑制剂Nivolumab在先前治疗的转移性肾细胞癌（mRCC）患者的3期试验中，与依维莫司相比，改善了总生存期。我们在一项假说产生的前瞻性mRCC试验中研究了nivolumab的免疫调节活性。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2016年第22期|共11页
作者
Choueiri Toni K.; Fishman Mayer N.; Escudier Bernard; McDermott David F.; Drake Charles G.; Kluger Harriet; Stadler Walter M.; Perez-Gracia Jose Luis; McNeel Douglas G.; Curti Brendan; Harrison Michael R.; Plimack Elizabeth R.; Appleman Leonard; Fong Lawrence; Albiges Laurence; Cohen Lewis; Young Tina C.; Chasalow Scott D.; Ross-Macdonald Petra; Srivastava Shivani; Jure-Kunkel Maria; Kurland John F.; Simon Jason S.; Sznol Mario;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma [J] . Choueiri Toni K., Fishman Mayer N., Escudier Bernard, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第22期

机译：尼伐单抗在转移性肾细胞癌中的免疫调节活性
2. Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab? [J] . Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2020,第4期

机译：耐久的反应后患有转移性肾细胞癌中的Nivolumab：肾毒性是预测Nivolumab的益处的标记吗？
3. Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041 Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment? [J] . Giuliani Jacopo, Bonetti Andrea European urology . 2018,第3期

机译：Re：Michal Sarfaty，Moshe Leshno，Noa Gordon等。晚期肾细胞癌中Nivolumab的成本效果。 EUR UROL。在新闻。 http://dx.doi.org/10.1016/j.eururo.2017.07.041二线治疗转移性肾细胞癌。可以免疫疗法被认为是具有成本效益的治疗方法吗？
4. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma [O] . Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, -1

机译：尼伐单抗在转移性肾细胞癌中的免疫调节活性
7. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma [O] . Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, 2016

机译：肾病肾细胞癌中Nivolumab的免疫调节活性

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅